Premium
FTS3‐02‐01: ETHNORACIAL DISPARITIES IN DRIVING OUTCOMES AMONG OLDER ADULTS IN THE UNITED STATES
Author(s) -
Babulal Ganesh M.,
Williams Monique M.,
Stout Sarah Holtz,
Roe Catherine M.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2760
Subject(s) - cinahl , ethnic group , gerontology , medicine , scopus , demography , population , medline , psychological intervention , environmental health , psychiatry , sociology , anthropology , political science , law
the use of biomarkers. However, while the FDA has approved the use of amyloid PET, the Center for Medicare and Medicaid Services does not cover reimbursement. As such, through the Coverage with Evidence Development procedure, the IDEAS study is underway to determine if amyloid imaging will affect the outcome of patients. Appropriate use criteria have been published to indicate when amyloid PET is appropriate. Clinical cases will be shown to demonstrate these circumstances. However, the clinical uptake of amyloid imaging in the United States has been slow. The cost of the scans is a limiting factor for clinicians and patients. In addition, the availability and distribution of the PET tracers by the manufacturers can be problematical. While the scans are specific for amyloid, the role of amyloid in clinical conditions vary While amyloid is likely the primary cause of cognitive impairment in familial AD, it is only one component in the causal pathway of older persons. For example, in cognitively impaired persons in their 70s or 80s, amyloid may be present but is likely only a part of the explanation of the underlying cognitive impairment, and the role of amyloid may be more difficult to interpret. Case examples will be shown of this issue. Conclusions: Amyloid imaging has been a major advancement in the field of aging and dementia. The IDEAS study will be important with respect to payment issues, and additional longitudinal data will be needed to determine the role of interpreting amyloid scans along the spectrum of cognition and aging.